Advertisement

'Janus Kinase-ing' Up the Treatment of Primary Myelofibrosis

Combining JAK-inhibitors with agents that target parallel prosurvival pathways or agents that enhance hematopoiesis may enhance efficacy and/or mitigate on-target myelosuppression, thereby extending the therapeutic benefits observed with JAK-inhibitors alone.

 Curr Opin Hematol

click me